Skip to main content
Top
Published in: Breast Cancer Research 4/2005

Open Access 01-08-2005 | Research article

Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2and mutation-negative breast cancer families

Authors: Hannaleena Eerola, Päivi Heikkilä, Anitta Tamminen, Kristiina Aittomäki, Carl Blomqvist, Heli Nevanlinna

Published in: Breast Cancer Research | Issue 4/2005

Login to get access

Abstract

Introduction

Our aim was to evaluate the relationship of patients' age to histopathological features of hereditary breast tumours in a series of breast cancer families not selected for age at diagnosis. In sporadic breast cancer, tumours from premenopausal patients have been shown to differ from those of postmenopausal patients, but this phenomenon has been little studied among familial patients.

Methods

Representative areas of all available breast cancer tissue specimens (n = 262) from 25 BRCA1, 20 BRCA2, and 74 non-BRCA1/2 breast cancer families were punched into a tissue microarray. Immunohistochemical staining of oestrogen receptor, progesterone receptor, ERBB2, and p53 as well as the histology and grade of tumours in these three groups of families were studied in different age groups and compared with each other.

Results

We found that only breast cancers from young (<50 years) BRCA1 + patients represent features documented as being typical of BRCA1-associated cancers, such as high tumour grade, negativity for oestrogen and progesterone receptors, and overexpression of p53. Among the BRCA2 families, the opposite was found, with a significantly higher frequency of tumours negative for oestrogen and progesterone receptors among the older patients than among the other groups, but no distinctive tumour characteristics among the younger BRCA2 patients.

Conclusion

Tumours of BRCA1 and BRCA2 carriers aged 50 years or more differed significantly from those of younger carriers. This difference may reflect different biological behaviour and pathways of tumour development among the older and the younger BRCA1 and BRCA2 patients, with impact also on prognosis and survival.
Literature
1.
go back to reference Phillips K, Andrulis IL, Goodwin PJ: Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: Are they prognostically different?. J Clin Oncol. 1999, 17: 3653-3663.PubMed Phillips K, Andrulis IL, Goodwin PJ: Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: Are they prognostically different?. J Clin Oncol. 1999, 17: 3653-3663.PubMed
2.
go back to reference Lakhani SR, van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton D, Consortium BCL: The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002, 20: 2310-2318. 10.1200/JCO.2002.09.023.CrossRefPubMed Lakhani SR, van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton D, Consortium BCL: The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002, 20: 2310-2318. 10.1200/JCO.2002.09.023.CrossRefPubMed
3.
go back to reference Malone KE, Daling JR, Ostrander EA: BRCA1 and medullary breast cancer. JAMA. 1998, 280: 1227-10.1001/jama.280.14.1227.CrossRef Malone KE, Daling JR, Ostrander EA: BRCA1 and medullary breast cancer. JAMA. 1998, 280: 1227-10.1001/jama.280.14.1227.CrossRef
4.
go back to reference Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumour subtypes in independent gene expression data sets. Proc Natl Acad Sci. 2003, 100: 8418-8423. 10.1073/pnas.0932692100.CrossRefPubMedPubMedCentral Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumour subtypes in independent gene expression data sets. Proc Natl Acad Sci. 2003, 100: 8418-8423. 10.1073/pnas.0932692100.CrossRefPubMedPubMedCentral
5.
go back to reference Foulkes W, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA: Germline BRCA1 mutations and basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003, 95: 1482-1485.CrossRefPubMed Foulkes W, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA: Germline BRCA1 mutations and basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003, 95: 1482-1485.CrossRefPubMed
6.
go back to reference Noguchi S, Kasugai T, Miki Y, Fukutomi T, Emi M, Nomizu T: Clinicopathologic analysis of BRCA1- or BRCA2 associated hereditary breast carcinoma in Japanese Women. Cancer. 1999, 85: 2200-22205. 10.1002/(SICI)1097-0142(19990515)85:10<2200::AID-CNCR14>3.0.CO;2-S.CrossRefPubMed Noguchi S, Kasugai T, Miki Y, Fukutomi T, Emi M, Nomizu T: Clinicopathologic analysis of BRCA1- or BRCA2 associated hereditary breast carcinoma in Japanese Women. Cancer. 1999, 85: 2200-22205. 10.1002/(SICI)1097-0142(19990515)85:10<2200::AID-CNCR14>3.0.CO;2-S.CrossRefPubMed
7.
go back to reference Vahteristo P, Syrjäkoski K, Eerola H, Kainu T, Holli K, Blomqvist C, Kallioniemi O, Nevanlinna H: Response: re: population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst. 2001, 93: 152-154. 10.1093/jnci/93.2.153.CrossRef Vahteristo P, Syrjäkoski K, Eerola H, Kainu T, Holli K, Blomqvist C, Kallioniemi O, Nevanlinna H: Response: re: population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst. 2001, 93: 152-154. 10.1093/jnci/93.2.153.CrossRef
8.
go back to reference Eerola H, Heikkilä P, Tamminen A, Aittomäki K, Blomqvist C, Nevanlinna H: Histopathological features of breast tumours in BRCA1, BRCA2, and in mutation negative breast cancer families. Breast Cancer Research. 2004, Eerola H, Heikkilä P, Tamminen A, Aittomäki K, Blomqvist C, Nevanlinna H: Histopathological features of breast tumours in BRCA1, BRCA2, and in mutation negative breast cancer families. Breast Cancer Research. 2004,
9.
go back to reference Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S, Abner A, Recht A, Vicini F, Harris JR: Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol. 1994, 12: 888-894.PubMed Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S, Abner A, Recht A, Vicini F, Harris JR: Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol. 1994, 12: 888-894.PubMed
10.
go back to reference Talley LI, Grizzle WE, Waterbror JW, Brown D, Weiss H, Frost AR: Hormonen receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopaussal women. Int J Cancer. 2002, 98: 118-127. 10.1002/ijc.10171.CrossRefPubMed Talley LI, Grizzle WE, Waterbror JW, Brown D, Weiss H, Frost AR: Hormonen receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopaussal women. Int J Cancer. 2002, 98: 118-127. 10.1002/ijc.10171.CrossRefPubMed
11.
go back to reference Anderson WF, Chu KC, Chang S, Sherman ME: Comparison of age-spesific insidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev. 2004, 13: 1128-1135.PubMed Anderson WF, Chu KC, Chang S, Sherman ME: Comparison of age-spesific insidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev. 2004, 13: 1128-1135.PubMed
12.
go back to reference Eerola H, Blomqvist C, Pukkala E, Pyrhönen S, Nevanlinna H: Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients?. Eur J Cancer. 2000, 36: 1143-1148. 10.1016/S0959-8049(00)00093-9.CrossRefPubMed Eerola H, Blomqvist C, Pukkala E, Pyrhönen S, Nevanlinna H: Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients?. Eur J Cancer. 2000, 36: 1143-1148. 10.1016/S0959-8049(00)00093-9.CrossRefPubMed
13.
go back to reference Vehmanen P, Friedman LS, Eerola H, Sarantaus L, Pyrhönen S, Ponder BAJ, Muhonen T, Nevanlinna H: A low proportion of BRCA2 mutations in Finnish Breast cancer families. Am J Hum Genet. 1997, 60: 1050-1058.PubMedPubMedCentral Vehmanen P, Friedman LS, Eerola H, Sarantaus L, Pyrhönen S, Ponder BAJ, Muhonen T, Nevanlinna H: A low proportion of BRCA2 mutations in Finnish Breast cancer families. Am J Hum Genet. 1997, 60: 1050-1058.PubMedPubMedCentral
14.
go back to reference Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L, Kainu T, Syrjäkoski K, Pyrhönen S, Kallioniemi O, et al: Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet. 1997, 6: 2309-2315. 10.1093/hmg/6.13.2309.CrossRefPubMed Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L, Kainu T, Syrjäkoski K, Pyrhönen S, Kallioniemi O, et al: Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet. 1997, 6: 2309-2315. 10.1093/hmg/6.13.2309.CrossRefPubMed
15.
go back to reference Huusko P, Pääkkönen K, Launonen V, Pöyhönen M, Blanco G, Kauppila A, Puistola U, Kiviniemi H, Kujala M, Leisti J, et al: Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. Am J Hum Genet. 1998, 62: 1544-1548. 10.1086/301880.CrossRefPubMedPubMedCentral Huusko P, Pääkkönen K, Launonen V, Pöyhönen M, Blanco G, Kauppila A, Puistola U, Kiviniemi H, Kujala M, Leisti J, et al: Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. Am J Hum Genet. 1998, 62: 1544-1548. 10.1086/301880.CrossRefPubMedPubMedCentral
16.
go back to reference Sarantaus L, Huusko P, Eerola H, Launonen V, Vehmanen P, Rapakko K, Gillanders E, Syrjäkoski K, Kainu T, Vahteristo P, et al: Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. Eur J Hum Genet. 2000, 8: 757-763. 10.1038/sj.ejhg.5200529.CrossRefPubMed Sarantaus L, Huusko P, Eerola H, Launonen V, Vehmanen P, Rapakko K, Gillanders E, Syrjäkoski K, Kainu T, Vahteristo P, et al: Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. Eur J Hum Genet. 2000, 8: 757-763. 10.1038/sj.ejhg.5200529.CrossRefPubMed
17.
go back to reference Vahteristo P, Bartkowa J, Eerola H, Syrjäkoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomäki K, Heikkilä P, et al: A CHK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 2002, 71: 432-438. 10.1086/341943.CrossRefPubMedPubMedCentral Vahteristo P, Bartkowa J, Eerola H, Syrjäkoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomäki K, Heikkilä P, et al: A CHK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 2002, 71: 432-438. 10.1086/341943.CrossRefPubMedPubMedCentral
18.
go back to reference Vaziri AJ, Krumroy LM, Elson P, Budd GT, Darlington G, Myles J, Tubbs RR, Casey G: Breast tumour immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res. 2001, 7: 1937-1945.PubMed Vaziri AJ, Krumroy LM, Elson P, Budd GT, Darlington G, Myles J, Tubbs RR, Casey G: Breast tumour immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res. 2001, 7: 1937-1945.PubMed
19.
go back to reference Antoniou AC, Pharoah P, Narod S, Risch H, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johansson OT, Borg A, et al: Average risks of breast and ovarian cancer associated with mutations in BRCA1 or BRCA2 detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003, 72: 1117-1130. 10.1086/375033.CrossRefPubMedPubMedCentral Antoniou AC, Pharoah P, Narod S, Risch H, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johansson OT, Borg A, et al: Average risks of breast and ovarian cancer associated with mutations in BRCA1 or BRCA2 detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003, 72: 1117-1130. 10.1086/375033.CrossRefPubMedPubMedCentral
20.
go back to reference Foulkes W, Metcalfe K, Sun P, Hanna WM, Lynch H, Ghadirian P, Tung N, Olopade O, Weber BL, McLennan J, et al: Estrogen reseptor status in BRCA1- and BRCA2-related breast cancer: The influence of age, grade, and histological type. Clin Cancer Res. 2004, 10: 2029-2034.CrossRefPubMed Foulkes W, Metcalfe K, Sun P, Hanna WM, Lynch H, Ghadirian P, Tung N, Olopade O, Weber BL, McLennan J, et al: Estrogen reseptor status in BRCA1- and BRCA2-related breast cancer: The influence of age, grade, and histological type. Clin Cancer Res. 2004, 10: 2029-2034.CrossRefPubMed
21.
go back to reference Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatch MJ, Sauter G, Kallioniemi O: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Med. 1998, 4: 844-847. 10.1038/nm0798-844.CrossRefPubMed Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatch MJ, Sauter G, Kallioniemi O: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Med. 1998, 4: 844-847. 10.1038/nm0798-844.CrossRefPubMed
22.
go back to reference Gillet CE, Springall RJ, Barnes DM, Hanby AM: Multiple tissue core arrays in histopathology research: a validation study. J Pathol. 2000, 192: 549-553. 10.1002/1096-9896(2000)9999:9999<::AID-PATH721>3.0.CO;2-0.CrossRef Gillet CE, Springall RJ, Barnes DM, Hanby AM: Multiple tissue core arrays in histopathology research: a validation study. J Pathol. 2000, 192: 549-553. 10.1002/1096-9896(2000)9999:9999<::AID-PATH721>3.0.CO;2-0.CrossRef
23.
go back to reference Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, Pruss D, Tavtigian SV, Teng DH, Adey N, et al: BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA. 1997, 278: 1242-1250. 10.1001/jama.278.15.1242.CrossRefPubMed Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, Pruss D, Tavtigian SV, Teng DH, Adey N, et al: BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA. 1997, 278: 1242-1250. 10.1001/jama.278.15.1242.CrossRefPubMed
24.
go back to reference Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997, 336: 1409-1415. 10.1056/NEJM199705153362002.CrossRefPubMed Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997, 336: 1409-1415. 10.1056/NEJM199705153362002.CrossRefPubMed
25.
go back to reference Chan-Claude J, Dong J, Schmidt S, Shayeghi M, Komitowski D, Becher H, Stratton MR, Royer-Pokora B: Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes. J Med Genet. 1998, 35: 116-121.CrossRef Chan-Claude J, Dong J, Schmidt S, Shayeghi M, Komitowski D, Becher H, Stratton MR, Royer-Pokora B: Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes. J Med Genet. 1998, 35: 116-121.CrossRef
26.
go back to reference Parmigiani G, Berry D, Aguilar O: Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998, 62: 145-158. 10.1086/301670.CrossRefPubMedPubMedCentral Parmigiani G, Berry D, Aguilar O: Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998, 62: 145-158. 10.1086/301670.CrossRefPubMedPubMedCentral
27.
go back to reference Vahteristo P, Eerola H, Tamminen A, Blomqvist C, Nevanlinna H: A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Brit J Cancer. 2001, 84: 704-708. 10.1054/bjoc.2000.1626.CrossRefPubMedPubMedCentral Vahteristo P, Eerola H, Tamminen A, Blomqvist C, Nevanlinna H: A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Brit J Cancer. 2001, 84: 704-708. 10.1054/bjoc.2000.1626.CrossRefPubMedPubMedCentral
28.
go back to reference Gilpin CA, Carson N, Hunter AGW: A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetic center. Clin Genet. 2000, 58: 299-308. 10.1034/j.1399-0004.2000.580408.x.CrossRefPubMed Gilpin CA, Carson N, Hunter AGW: A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetic center. Clin Genet. 2000, 58: 299-308. 10.1034/j.1399-0004.2000.580408.x.CrossRefPubMed
29.
go back to reference Lidereau R, Eisinger F, Champème M-H, Noguès C, Bièche I, Birnbaum D, Pallud C, Jacquemier J, Sobol H: Major Improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res. 2000, 60: 1206-1210.PubMed Lidereau R, Eisinger F, Champème M-H, Noguès C, Bièche I, Birnbaum D, Pallud C, Jacquemier J, Sobol H: Major Improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res. 2000, 60: 1206-1210.PubMed
30.
go back to reference Eisinger F, Noguès C, Guinebretiere J, Peyrat J, Bardou V, Noguchi T, Vennin P, Sauvan R, Lidereau R, Birnbaum D, et al: Novel indications for BRCA1 screening using individual clinical and morphological features. Int J Cancer. 1999, 84: 263-267. 10.1002/(SICI)1097-0215(19990621)84:3<263::AID-IJC11>3.0.CO;2-G.CrossRefPubMed Eisinger F, Noguès C, Guinebretiere J, Peyrat J, Bardou V, Noguchi T, Vennin P, Sauvan R, Lidereau R, Birnbaum D, et al: Novel indications for BRCA1 screening using individual clinical and morphological features. Int J Cancer. 1999, 84: 263-267. 10.1002/(SICI)1097-0215(19990621)84:3<263::AID-IJC11>3.0.CO;2-G.CrossRefPubMed
Metadata
Title
Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2and mutation-negative breast cancer families
Authors
Hannaleena Eerola
Päivi Heikkilä
Anitta Tamminen
Kristiina Aittomäki
Carl Blomqvist
Heli Nevanlinna
Publication date
01-08-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 4/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1025

Other articles of this Issue 4/2005

Breast Cancer Research 4/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine